

Performance in Delivering Q3 19-20

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same in Both if Different Numbers)	Maximum Number Of Patients Agreed (Enter Same in Both if Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
43731	18/LO/1749	249644	Efficacy and Safety of PF-04965842 in subjects aged 12 years and above, with Moderate-to-Severe AD	Number Agreed	1	1	Date Agreed	03/04/2019	1	03/04/2019	1	Recruitment Finished	
43732	17/NE/0174	224141	Evaluation of the MCM5 ELISA in bladder cancer recurrence	Number Agreed	40	40	Date Agreed	30/06/2019	24	30/06/2019	24	Recruitment Finished	
43733	18/WS/0172	251636	A randomized, open-label, multi-center, controlled clinical study to compare MAP-CUTIS with Dermabond Advanced in closure of surgical incisions and lacerations =15cm	Number Agreed	1	1	Date Agreed	22/07/2019	1	22/07/2019	1	Recruitment Finished	
43734	19/SC/0204	260266	A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active Ulcerative Colitis	Number Agreed	5	5	Date Agreed	31/12/2021	0	21/08/2019	0	Withdrawn By Host	Abandoned due to local capacity issues
43735	19/WM/0204	261470	A 52-Week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Operationally Seamless Phase 2b/3, Parallel-group Study to Assess the Efficacy and Safety of Brazikumab in Participants with Moderately to Severely Active	Number Agreed	5	5	Date Agreed	05/12/2021	0	21/08/2019	0	Withdrawn By Host	Abandoned due to local capacity issues
43736	19/YH/0072	257713	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 CO-ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE-TO-SEVERE AD	Range Agreed	0	0	Date Agreed	22/11/2019	0	22/11/2019	0	Recruitment Finished	No eligible patients